Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 5/20 | 0.49 |
| ▸ | GABRD | O14764 | 5/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.49 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.49 |
| ▸ | GABRE | P78334 | 5/20 | 0.49 |
| ▸ | GABRA6 | Q16445 | 5/20 | 0.49 |
| ▸ | GABRG1 | Q8N1C3 | 5/20 | 0.49 |
| ▸ | GABRG3 | Q99928 | 5/20 | 0.49 |
| ▸ | GABRQ | Q9UN88 | 5/20 | 0.49 |
| ▸ | PIM1 | P11309 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29416622 | 0.87 | PIM1 (0.58) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2588529 | 0.87 | PIM1 (0.58) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL47040 | 0.84 | PIM1 (0.51) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30593469 | 0.84 | PIM1 (0.51) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL571194 | 0.84 | NPC1 (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL570364 | 0.84 | NPC1 (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2592127 | 0.79 | MAOA (0.67) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30284875 | 0.79 | MAOA (0.67) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1995343 | 0.78 | GABRP (0.38) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2000388 | 0.77 | PIM1 (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883782-B2 | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883782-B2 | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883782-B2 | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2328903-B1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-2328903-B1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2014-03-05 | — | — | EP | disclosed |
| US-8426447-B2 | Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426447-B2 | Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426447-B2 | Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2547685-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | Amgen Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011115938-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| EP-2328903-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010030954-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | GABRP 1620/4885GABRD 1563/4885GABRA1 1446/4885 |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | GABRP 1829/4885GABRD 1866/4885GABRA1 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.